In 1986 Gibbons and Read confirmed that patients with anal fissures had elevated anal resting pressures and they hypothesized that elevated anal resting pressures led to tissue ischemia
Trang 1improved outcomes in colon and rectal surgery
155 Consten CJ, Siors FJM, Noten HJ et al Anorectal surgery
in human immunodeficiency virus-infected patients Dis
Colon Rectum 1995; 38: 1169–75
156 Miles AJG, Mellor CH, Gazzard B et al Surgical management
of anorectal disease in HIV-positive homosexuals Br J Surg
1990; 77: 869–71
157 Munoz-Villasmil J, Sands L, Hellinger M Management of
perianal sepsis in immunosuppressed patients Am Surg
2001; 67: 484–6
158 Onerheim RM A case of perianal mucinous
adenocarci-noma arising in a fistula-in-ano: a clue to the early
patho-logic diagnosis Am J Clin Pathol 1988; 89: 809–12
159 Seya T, Tanaka N, Shinji S et al Squamous cell carcinoma arising from recurrent anal fistula J Nippon Med Sch 2007; 74: 319–24
160 Korelitz BI Carcinoma of the intestinal tract in Crohn’s dis-ease: results of a survey conducted by the National Foundation for Ileitis and Colitis Am J Gastroenterol 1983; 78: 44–6
161 Smith R, Hicks D, Tomljanovich PI et al Adenocarcinoma arising from chronic perianal Crohn’s disease: case report and review of the literature Am Surg 2008; 74: 59–61
162 Sarani B, Orkin BA Squamous cell carcinoma arising in an unhealed wound in Crohn’s disease South Med J 1997; 90: 940–2
Trang 220 Surgery and nonoperative therapy of anal fissure
Jaime L Bohl and Alan J Herline
Challenging CaSe
A 35-year-old woman presents with a recurrent posterior anal
fissure She had a left lateral anal sphincterotomy 4 years ago for
an unresponsive anal fissure Her fissure healed until 6 months
ago She has had two previously vaginal deliveries Exam reveals
a posterior anal fissure with exposed sphincter muscle and a
sen-tinel skin tag Anal manometry revealed mildly decreased
rest-ing pressure and a hypertonic squeeze pressure The patient’s
symptoms have not responded to stool softners and topical
medication
CaSe ManageMent
A repeat sphincterotomy is relatively contraindicated due to the
decreased sphincter function An acceptable surgical option is an
advancement flap
introduCtion
An anal fissure is a longitudinal tear or ulcer in the anal canal
from the dentate line to the anal verge Fissures affect both genders
equally, across age groups with young and middle aged adults
con-stituting the majority of patients.(1) Although the true incidence
is not known, anal fissure is common In a survey of Italian
proc-tology clinics, 10% of 15,000 consecutive referrals were diagnosed
with anal fissure.(2)
Fissures can be classified by etiology, location, and chronicity It
is hypothesized that most fissures are caused by trauma to the anal
canal, usually from passage of hard stool Anal fissures are
com-monly located in the posterior midline (75%), although a smaller
percentage can be found in the anterior midline (13%) and an
anterior and posterior location may be seen simultaneously (11%)
Anterior fissures are seen more commonly in women (19%).(1)
Fissures may be associated with other chronic medical conditions
such as Crohn’s disease, HIV/AIDS, tuberculosis, syphilis, or anal
carcinoma Fissures in patient with these conditions typically
occur off the midline and may be multiple or irregular (Figure
20.1) These fissures are best treated according to the underlying
disease state Early or acute fissures are a simple linear tear in the
anoderm Fissures that have been present for >4 weeks show signs
of chronicity: the base of the fissure reveals internal sphincter fibers
with indurated edges, and a sentinel pile (cranial) or hypertrophied
apical papilla (distal) The chronicity of a fissure is important to
discern from patient history and clinical exam as this will affect
treatment recommendations
PathPhySiology
The exact mechanisms leading to acute anal fissure and the
factors that encourage fissure chronicity have been the subject
of debate However, anatomic and physiologic studies suggest
an ischemic etiology to anal fissure chronicity In 1986 Gibbons
and Read confirmed that patients with anal fissures had elevated
anal resting pressures and they hypothesized that elevated anal resting pressures led to tissue ischemia and ulceration within the anal canal.(3) This hypothesis was further supported by anatomic studies performed by Klosterhalfen and colleagues who showed that the posterior anal canal has a limited blood supply compared to the rest of the anal canal.(4) The decreased blood supply to the posterior anal canal was evident through the lack of inferior rectal artery branches to the posterior anal com-missure in 85% of postmortem specimens, and the decreased capillary density in histologic specimens.(4) Schouten and colleagues put these findings together when they demonstrated
an inverse relationship between anal resting pressure and ano-dermal blood flow.(5) Therefore, patients with anal fissure have less blood flow to their posterior midline secondary to anal hypertonia The ischemia in the posterior midline allows per-sistence of anal fissures and poor healing Treatments for anal fissure are therefore aimed at decreasing anal hypertonia and increasing anodermal blood flow
Anal fissures can be exquisitely painful despite the small size
of the lesion Patients complain of sharp, persistent pain dur-ing and after defecation, which may lead patients to avoid bowel movements Patients may also notice blood on the toilet tissue or coating the stool with limited bleeding or perianal swelling
POSTERIOR
ANTERIOR
Acute and Chronic anal fissure
Acute and Chronic anal fissure
Crohn’s disease Ulcerative colitis Syphilis Tuberculosis Leukemia Cancer HIV
Crohn’s disease Ulcerative colitis Syphilis Tuberculosis Leukemia Cancer HIV
Figure 20.1 Fissure location related to etiology.
Trang 3improved outcomes in colon and rectal surgery
diagnoSiS
The clinician should inquire about known risk factors for fissure
including alteration in bowel habits (constipation or diarrhea),
childbirth, previous anorectal surgery, or associated medical
con-ditions The clinician should also inquire to previous episodes
of the presenting symptom complex The natural history of anal
fissure is one that waxes and wanes, sometimes with healing
between recurrences
Anal fissure can be diagnosed by inspection of the anus Patients
are usually too symptomatic to allow for digital examination or
anoscopy at the initial visit If the clinician suspects another
diag-nosis because of an atypical location, the presence of multiple or
chronic fissures, or a fissure cannot be diagnosed by inspection, then
exam under anesthesia may be necessary Suspicion of an alternative
diagnosis may warrant biopsy and culture of the anal lesions
treatMent
Anal fissures have been treated with a variety of medical and
surgi-cal therapies A growing body of randomized controlled trials has
helped to guide current treatment recommendations for anal
fis-sure Currently available treatments include conservative therapy,
nitrates, calcium channel blockers, botulinum toxin, anal dilation,
open or closed lateral sphincterotomy, and anal advancement flap
Conservative therapy comprises increased dietary fluid and fiber,
sitz baths, and stool softeners Nitrates may include ointments of
nitroglycerin (NTG) or glyceryl trinitrate (GTN), nitroglycerin
transdermal patch, or other nitrate analogs such as isosorbide
dinitrate (IDN) or isosorbide mononitrate (IMN) Calcium
chan-nel blockers have been used in ointment or tablet form (diltiazem
or nifedipine) Finally, botulinum toxin (BT) has been used in
the treatment of anal fissure It is sold in two commercially
avail-able preparations, Dysport (Speywood Biopharm Ltd, Wrexham,
UK) and Botox (Allergan, Irvine, CA, USA) Both preparations of
BT have been shown to have equal efficacy in the treatment of
chronic anal fissure (6) with 100 units of Dysport toxin having the
bioequivalence of 20 units of Botox All of these medical and
sur-gical treatments have been used in randomized controlled trials to
assess the effect on fissure healing rates, anal resting pressure, pain,
and fissure recurrence Other treatment effects which are
impor-tant to consider are complications such as incontinence to flatus or
stool, headache, hypotension, and allergic reactions Importantly,
two recent meta-analyses of all medical and surgical treatments
used for anal fissure are available.(7–10) This has lead to improved
decision making regarding the treatment of anal fissure
Conservative therapy is often used as a comparison to other
medical or surgical treatment The effect of conservative therapy on
healing rate for anal fissure has been 50% for acute (11) and 34%
for chronic anal fissures.(7) Therefore, other medical and surgical
treatments should be tested with this therapy in mind The effect
of conservative therapy on anal fissure healing rate, reduction in
symptoms, and safety profile has lead to the recommendation by
the American Society of Colon and Rectal Surgeons for
conserva-tive therapy to be the first line treatment of anal fissure.(12)
aCute anal FiSSure
Clinical experience dictates that over half of acute anal fissures will
heal within several weeks Therefore, most clinicians recommend
conservative therapy for acute anal fissure Conservative therapy consists of fiber supplements and sitz baths with or without the use
of topical anesthetics However, few randomized controlled trials have evaluated acute anal fissure healing with conservative therapy
as compared to no therapy One trial compared warm sitz baths and 10 g of unprocessed bran to 2% lignocaine ointment or 2% hydrocortisone ointment applied in the anal canal twice per day (13) After 3 weeks of treatment, patients treated with bran and sitz baths had significantly more healed fissures (88%) than patients treated with lignocaine ointment (60%) Unfortunately, patients with healed fissures were not followed long-term and rates of fis-sure recurrence were not meafis-sured One randomized controlled trial does suggest the ability of long-term conservative therapy to prevent fissure recurrence.(14) Ninety patients with recently healed posterior anal fissures were randomized and blinded to three dif-ferent treatments groups for 1 year Patients received either 5 g unprocessed bran three times a day, 2.5 g unprocessed bran plus 2.5 g placebo, or 5 g placebo Patients receiving 5 g of unprocessed bran over 1 year had significantly fewer recurrences of anal fissure (16%) as compared to patients who received the lower bran dose (60%) or placebo (60%) In addition, within 6 months of discon-tinuing treatment, the recurrence rate between the three groups was similar Finally, one study evaluated the role of sitz baths in symptom relief and acute anal fissure healing while also providing psyllium supplementation over 4 weeks.(15) Although there was
a trend toward improved pain scores after defecation and overall intensity of pain, there were no significant differences in fissure healing between groups (85%) The authors hypothesize that sitz baths provide transient pain relief via a thermosphincteric reflex which allows for decrease in sphincter tone and temporary pain relief However, sitz baths do not lead to long-term reduction in anal tone that allows for fissure healing Overall, these studies show that fiber therapy is more effective in preventing acute anal fissure recurrence, but only suggest that fiber therapy can improve acute fissure healing
In an effort to improve acute anal fissure healing rates and maintain healing, some investigators have added anal dilation or pharmacologic agents to conservative treatment One study shows
no additional therapeutic benefit of twice daily anal dilation in combination with stool softener and lignocaine jelly.(16) Another small randomized study that included patients with both acute and chronic fissures compared topical nitroglycerin to topical xylocaine.(17) In patients who had acute fissures, those receiving topical nitroglycerin had fissure healing rates of 92% compared
to 0% of the control arm after 14 days of therapy This treatment effect persisted, with the same number of patients in the nitro-glycerin group maintaining healing at 28 days compared to 50%
of patients who received xylocaine ointment No long-term fol-low-up data was provided and all treatment failures were referred for lateral sphincterotomy A larger randomized trial examined the healing rate of acute anal fissure after treatment with 0.2% nifedipine ointment twice daily compared to conservative therapy (18) Patients who received nifedipine treatment had higher fissure healing rates compared to conservative therapy (98 vs 60%) after
4 weeks of treatment One novel approach to achieve acute anal fissure healing has been to compare the efficacy of gonyautoxin,
a paralyzing phytotoxin, to normal saline placebo which are both
Trang 4injected into the internal anal sphincter.(19) This study included
17 patients with acute anal fissure and was eventually unblinded
secondary to a large treatment effect of the toxin Patients with
acute anal fissures had a healing rate of 100% at 15 days as
com-pared to 0% of the 3 patients who received placebo All patients
who were injected with the toxin showed a significant decrease
in anal resting pressure from baseline Complications included
minor bleeding but did not result in any cases of incontinence to
stool or flatus After 14 months of follow-up this treatment effect
has been maintained In all, these studies show that the addition of
a pharmacologic agent can increase the healing rates of acute anal
fissure; however, larger trials are needed to replicate these results
ChroniC anal FiSSure
Medical Therapy
Anal fissure chronicity is attributed to sphincter hypertonia and
decreased anodermal blood flow in the posterior anal canal
Pharma-cologic manipulation of the hypertonic internal anal sphincter has
been sought, given the permanent changes that can occur with
surgi-cal intervention Medisurgi-cal treatments that result in temporary
relaxa-tion of the internal anal sphincter or chemical sphincterotomy have
been used in the treatment of chronic anal fissure
Nitrates
Nitrates have been shown to have a relaxing effect on the human
internal anal sphincter (IAS) Ex vivo studies on the human
IAS show that nitric oxide (NO) mediates sphincter relaxation through enteric inhibitory neurons which are found within the muscle fibers.(20) Nitrates which are NO donors are readily avail-able pharmacologic agents Loder et al demonstrated that GTN ointment causes a decrease in anal resting pressure in normal and anal fissure patients which was comparable to sphincterotomy (21) Schouten and colleagues then showed that anal resting pres-sure decreased and anodermal blood flow increased after chronic anal fissure patients were treated with isosorbide dinitrate.(22) They concluded that the reduction in anal sphincter pressure and increased blood would contribute to early pain relief, while fis-sure healing would require more time More recent studies have shown conflicting data on the ability of nitrates to significantly decrease anal resting pressure in chronic anal fissure patients Thornton et al clarified these conflicting results with a regression analysis which showed that patients who were mostly likely to heal their fissure in response to nitrate therapy were those with higher pretreatment anal resting pressures and a greater percent reduction in posttreatment anal resting pressures.(23) Based on these physiologic studies, nitrates have become an obvious choice for the pharmacologic treatment of chronic anal fissure
Nitrates versus Placebo
There are ten randomized controlled trials in the English litera-ture which compare nitrate therapy to placebo or conservative therapy in adults with chronic anal fissure (Table 20.1) There have been a variety nitrate preparations, ointment strengths,
Table 20.1 Randomized Controlled Trials of Nitrate Therapy versus Placebo for the Treatment of Chronic Anal Fissure.
author/year
number Patients
treatment groups (%)
length treatment (weeks)
Fissure healing rates (%) Side effects (%)
Follow-up (months)
recurrence (%)
Lund 1997 (24) 80 P vs 0.2 GTN
BID
8 8 vs 68
(p < 0.0001)
HA: 18 vs 58 (p < 0.05)
4 11.5%
GTN Kennedy 1999 (27) 43 P vs 0.2 GTN
TID
4 16 vs 46
(p = 0.001)
HA: 21 vs 29 Discontinued treatment: 13
29 NR
Altomere 2000 (26) 132 P vs 0.2 GTN
BID
4 52 vs 49
(p = ns)
HA: 8 vs 34 (p = 0.001) Orthostatic hypotension: 6
3 19% GTN
Chaudhuri 2001 (25) 19 P vs 0.2 GTN
BID
6 22 vs 70
(p < 0.05)
Not reported 3 None
Maan 2004 (28) 64 P / 5 xylocaine /
proctosedyl / 0.2 GTN BID
6 25 vs 94
(p < 0.0001)
HA: 0 vs 19 None NR
Carapeti 1999 (29) 70 P / 0.2 / 0.2+0.1qwk
GTN TID
8 32 vs 67 all GTN
(p = 0.008)
HA: 27 vs 72 all GTN (p < 0.001)
9 43 vs 29
(p = 0.7)
Bailey 2002 (30) 304 P / 0.1 / 0.2 / 0.4 NTG
BID or TID
8 50- all groups
(p < 0.62)
Discontinued treatment: 3.3 None NR
Scholfield 2003 (31) 200 P / 0.1 / 0.2 / 0.4 GTN
BID
8 38 vs 47 all GTN
(p = 0.3)
HA: 13 vs 31 all GTN (p < 0.01)
None NR
Wierre 2001 (31) 37 P vs 1 IDN
5x/day
10 35 vs 85
(p < 0.003)
HA:18 vs 45 10 33 vs 12
Tankova 2002 (32) 19 P vs 0.2 IMN
BID
3 22 vs 80 HA: 0 vs 20 3 None
Note: P = placebo; GTN = glyceryl trinitrate; BID = twice per day; HA = headache; TID = three times per day; NR = not recorded; NS = not statistically significant; NTG = nitroglycerin; IDN = isosorbide dinitrate; IMN = isosorbide 5-mononitrate.
Trang 5improved outcomes in colon and rectal surgery
schedules, treatment length, and instructions for nitrate
adminis-tration that have been utilized in these studies
Five randomized controlled trials have measured the effect of
0.2% GTN ointment in comparison to placebo.(24–28) In these
studies a total of 338 patients were instructed to apply an active
versus inert ointment to their anal canal either twice or three time
daily for a period of 4 to 8 weeks Outcome measures included
fissure healing, pain, mean anal resting pressure (MARP), fissure
recurrence, and ointment side effects Four of these studies were
able to measure an increase in anal fissure healing rates with
nitro-glycerin ointment compared to placebo.(24, 25, 27, 28) However,
there was a wide range of GTN treatment effect (8–52%
pla-cebo vs 46–94% GTN) The fifth and largest study included 132
patients and did not measure a difference in healing rates between
the placebo and GTN ointment (52% vs 49%).(26) In four
stud-ies, pain was reported as a secondary outcome In three studies
pain was significantly decreased after treatment compared to pain
at time of trial entry in both GTN and placebo groups.(24, 26, 27)
However, only one study measured a significant difference in pain
scores between GTN and placebo treatment groups.(28) All five
studies measured treatment effect on MARP Two studies
meas-ured a decrease in MARP after treatment compared to time at trial
entry for both placebo and GTN groups.(25, 26) In the other three
studies, only the GTN treatment group had a significant decrease
in MARP.(24, 27, 28) One trial reported loss of decreased MARP
48 hours after discontinuing GTN therapy.(27) The most
sig-nificant side effect of nitrate therapy was headache In four trials,
there was a higher rate of headaches in GTN patients (19–58%)
compared to placebo treated patients (0–21%).(24, 25, 27, 28)
There was also a difference in the severity of headache reported
between these two groups.(27) Ultimately, headaches lead to
sub-sequent decreases in dose or discontinuation of GTN for several
patients in each trial In two studies there was an attempt to follow
patients long-term.(24, 26) The rate of fissure recurrence in the
GTN treated group was 11.5–19% after 3–4 months of follow-up
Overall, these five trials suggest a slightly increased rate of anal
fis-sure healing with GTN ointment compared to placebo However,
there is an increased incidence and severity of headache with
GTN treatment which may require a decreased dose for continued
patient compliance Despite healing, there may be a high rate of
fissure recurrence within several months of follow-up
Three additional trials have tested the effect of increasing doses
of GTN ointment on anal fissure healing rate, MARP, pain scores,
headache, and anal fissure recurrence.(29–31) Two trials
com-pared placebo with 0.1%, 0.2% and 0.4% GTN ointment (B,S)
The third trial compared placebo with 0.2% GTN ointment and
an increasing dose of GTN ointment which started at 0.2% and
was increased by 0.1% every week to a dose of 0.6% GTN.(28) All
treatment was administered for 8 weeks and applied either BID or
TID In these trials there was only one that measured a difference
in fissure healing rate of the GTN treatment group compared to
placebo.(29) There were no differences found in fissure healing
rate with changes in GTN dose One trial reported a 21%
reduc-tion in pain when treated with 0.4% GTN compared to placebo
(30) There was no difference in pain scores between placebo and
GTN or between GTN doses in the other studies.(29, 31) Across
these three trials, MARP was not uniformly decreased in the nitrate
treated group compared to baseline All three studies reported a high incidence of headache in the GTN group (31–72%) com-pared to placebo (13–27%) Headaches were more frequent and severe with increasing dose of GTN ointment Follow-up was performed in one study One third of anal fissures that initially healed recurred within 9 months.(29) These trials demonstrate that increasing doses of GTN do not increase the rate of fissure healing or improve fissure related pain, but do result in more severe and frequent headaches Again, recurrence when reported, occurs in up to one-third of patients
Two additional studies have used alternative nitrate prepara-tions for the treatment of chronic anal fissure for comparison with placebo Wierre et al used 1% isosorbide dinitrate oint-ment five times per day for 10 weeks.(32) There was a significant difference in fissure healing rate between placebo and active oint-ments (35 vs 85%) However there was no significant change in MARP throughout the trial period There was also a significant incidence of headache in the treatment group (45%) compared to placebo (18%) with 10% of patients in the active treatment dis-continuing therapy Thirty-three percent of patients in the active treatment arm had fissure recurrence and requested alternative therapy Tankova et al used 0.2% isosorbide mononitrate on chronic anal fissures compared to placebo administered BID over
a 3 week treatment course.(33) Eighty percent in the active treat-ment arm healed their fissures compared to 20% in the placebo group Twenty percent in the active group had headaches which were treated with mild analgesics No recurrences were seen in
3 months of follow-up The authors of both these studies agree that different nitrate preparations can be used to treat chronic anal fissure but that more studies are required to determine the optimal preparation, dose, and schedule of nitrate therapy Two studies have compared 0.2% GTN ointment to a transder-mal nitroglycerin patch for either 6 or 8 weeks of treatment.(34, 35)
In both studies the transdermal patch was a 10 mg dose that was applied for either 12 or 24 hours These studies found that both preparations resulted in equivalent fissure healing rates at 6 weeks (65–73%), 8 weeks (63–67%) and 12 weeks (79–81%) One trial reported a decrease in pain from baseline by 50% in both the oint-ment and patch patients.(35) The rate of headache was substantially lower in one study (16–19%) (34) compared to another (63–72%) (35) but both studies reported the headache to be responsive to mild analgesics and equal in occurrence between the two treat-ment groups Six percent of patients in one study reported transient incontinence to flatus which had resolved by the time of trial resolu-tion.(35) Recurrence at 3 months for one trial occurred in 9–15% (34) patients and 25% in the other.(35) In all, 0.2% GTN ointment seems equivalent to transdermal patch in the rate of anal fissure
healing, pain relief, side effects, and recurrence
Overall, chronic anal fissure healing rates after treatment with nitrates (49%) may be slightly improved compared to placebo (37%).(7) Nitrate therapy may decrease pain associated with anal fissure but with a concomitant increase in headaches (27%) that can lead to noncompliance Given the side effect profile and high recurrence rates after nitrate therapy (33%), the patient may request alternative therapeutic interventions Nitrate therapy remains a treatment alternative for patients wanting to avoid surgery and does not exclude the patient from other therapies in the future
Trang 6Nitrates versus Sphincterotomy
Nitrate therapy has been compared to internal sphincterotomy for
the treatment of chronic anal fissure Six studies have compared
these two treatments in a randomized controlled fashion.(36–41)
(Table 20.2) Four studies found internal sphincterotomy to be
superior to nitrate therapy for fissure healing after 6–8 weeks
(36–39) The two studies which showed no difference in fissure
healing between treatment groups, were smaller and measured a
larger nitrate treatment effect than is traditionally seen (83–90%)
Richard and colleagues found nitrate therapy to help fissure related
pain despite poor fissure healing (36) Parellada and colleagues
found a posttreatment decrease in MARP from baseline in both
treatment groups (30%) without a significant difference between
groups.(39) Four studies found a significant rate of headaches
in nitrate treated patients.(36–38, 41) These headaches caused
significant problems with patient compliance and 20–30% of
patients discontinued ointment application In comparison, there
were relatively few and minor side effects in patients undergoing
sphincterotomy While one study measured a high rate of
postop-erative incontinence to flatus (44%), this decreased to 15% after
2 years follow-up.(39) Initially, Richards et al did not find any
difference in immediate postoperative continence scores between
patients treated with nitrates or sphincterotomy.(36) After 5 years,
the investigators contacted 62% of the study patients With the
use of a sensitive incontinence scale, there were still no
differ-ences in continence scores between the two groups However, 2/3
of patients reported some degree of incontinence Finally, fissure
recurrence occurred rarely in patients undergoing
sphincterot-omy (0–4%) compared to high rates of recurrence among patients
treated with nitrates (13–45%) In all, nitrates are significantly less
effective than sphincterotomy for fissure healing, acute relief of
pain, fissure recurrence, and number of treatment side-effects
when administered for treatment of chronic anal fissure
Calcium Channel Antagonists
Given the frequency of adverse side effects with nitrate therapy,
other medical treatments have been sought for patients with
chronic anal fissure Calcium channel antagonists have been used
as alternative agents for temporary chemical sphincterotomy Calcium is necessary for tonic contraction and spontaneous activ-ity in the IAS smooth muscle.(42) When IAS muscle is subjected
to a calcium channel antagonist, nifedipine, tone and spontaneous contraction of the muscle is inhibited Therefore, a calcium chan-nel antagonist may reduce the IAS hypertonia that is observed
in chronic anal fissure Indeed, nifedipine has been shown to decrease anal resting pressure in normal controls and patients with anal fissure or hemorrhoids.(43) Nifedipine decreased anal resting pressure by approximately 30% in all groups Decreased anal pressure is thought to cause increased anodermal blood flow and allow for fissure healing Carapeti and colleagues showed that diltiazem ointment significantly reduced anal resting pressure and allowed for 67% of patients with chronic anal fissure to heal over 8 weeks However, they were unable to measure a significant difference in anodermal blood flow using laser Doppler before and after diltiazem administration.(44) Due to the ability of cal-cium channel antagonists to reduce anal resting pressure, they have been used as alternatives to nitrates for chemical sphincter-otomy in patients with chronic anal fissure
Calcium Channel Antagonists versus Placebo
One study has compared the efficacy of a calcium channel antago-nist, nifedipine to a treatment consisting of lidocaine, and hydro-cortisone ointment for the treatment of chronic anal fissure.(45) (Table 20.3) One hundred and ten patients were given either 0.3% nifedipine ointment or 1.5% lidocaine plus 1.0% hydrocortisone ointment for twice daily application over 6 weeks Patients who were given nifedipine ointment had a significant reduction in anal resting pressure (11%) from baseline after 3 weeks of treatment In addition, 95% of these patients had a healed fissure after 6 weeks Positive treatment effects were not seen in the placebo treatment arm with manometric studies measuring a 4.4% increase in anal resting pressure, and only 16% of patients experienced fissure healing The patients did not report any side effects Six percent of patients treated with nifedipine had fissure recurrence, 66% were
Table 20.2 Randomized Controlled Trials of Nitrates versus Surgical Sphincterotomy for the Treatment of Chronic Anal Fissure.
author/
year
number
Patients
treatment groups (% ointment)
length of treatment (weeks)
Fissure healing (%)
overall Side-effects (%) ha %
iC Flatus (%)
Follow-up (months)
recurrence (%)
Oettle
1997 (40)
24 NTG/ LIS
TID
4 83 vs 100
Richard
2000 (36)
82 0.25/0.5 GTN/LIS
TID
6 30 vs 90
(p = 0.00) (p < 0.0001)84 vs 29 21 None 6 38 vs 3
Evans
2001 (37)
60 0.2 GTN/LIS
TID
8 61 vs 97
(p < 0.001) NR 33 7.4 5 45 vs 4
Libertiny
2002 (38)
70 0.2 GTN/LIS
TID
8 54 vs 100
(p = 0.02) NR 20 2.8 24 16 vs 2.8
Parellada
2004 (39)
54 0.2 IDN/LIS
TID
6 67 vs 96
(p < 0.001) (p = NR)30 vs 44 NR 44 @ 5 wk 15 @ 24 wk
24 13 vs 0
Mishra
2005 (41)
40 0.2 GTN/LIS
BID
6 90 vs 85
(p = 0.347) (p = NR)40 vs 70 15 15 4 NR
Note: NTG = nitroglycerin; LIS = lateral internal sphincterotomy; TID = three times per day; NS = not statistically significant; NR = not recorded; GTN = glyceryl trinitrate; IDN = isosorbide dinitrate.
Trang 7improved outcomes in colon and rectal surgery
retreated and, once again, their fissure healed This is in
compari-son to 55% recurrence in the placebo arm Of the 47 patients who
did not achieve fissure healing or who suffered a recurrence after
placebo treatment, 45 elected to have nifedipine treatment at the
study conclusion with a 95% healing rate While this study is
prom-ising for the use of nifedipine as an alternative to nitrate therapy for
chronic anal fissure, the extent of treatment effect is questionable
given the low fissure healing rate in the placebo arm
Calcium Channel antagonists versus Nitrates
Five studies have compared calcium channel antagonists to nitrate
therapy in patients with chronic anal fissure (Table 20.3) Three
of these studies have used 2% diltiazem ointment in comparison
to 0.2% or 0.5% GTN administered over 6–8 weeks.(46–48) All
three studies report no difference in anal fissure healing between
the GTN or diltiazem treated groups In all three studies, there
were more overall side effects and headaches in the nitrate treated
patients compared to the diltiazem treated patients In the
larg-est of the three studies, recurrence occurred sooner and more
frequently among patient receiving GTN compared to diltiazem
(48) Overall, diltiazem ointment has equal efficacy to GTN
oint-ment for anal fissure healing with fewer side effects, and possibly
a lower rate and longer interval to recurrence
Two studies used nifedipine preparations for comparison with
GTN for the treatment of chronic anal fissure.(49, 50) In one study,
a 0.2% nifedipine ointment (49) was used while oral nifedipine
was used in the other.(50) Ezri et al found the nifedipine
oint-ment to be superior to the GTN ointoint-ment in healing anal fissure
They also found a higher rate of overall side effects in the GTN
treated group However, both treatment arms were found to have
a high recurrence rate over 12 months (31–42%) In contrast, the
oral nifedipine was equivalent to GTN ointment in fissure healing,
recurrence, and side effects These two studies demonstrate that multiple preparations of calcium channel antagonists may be used for the treatment of chronic anal fissure with equal healing efficacy and fewer side effects than GTN ointment
Calcium Antagonists versus Sphincterotomy
Two studies have compared calcium channel blockade (oral and ointment preparations) to lateral internal sphincterotomy in the treatment of chronic anal fissure.(49, 50) (Table 20.3) While both studies measure a high rate of fissure healing in patients undergo-ing sphincterotomy (95–100%), there is a wide range in the fissure healing rate for patients receiving nifedipine treatment (16–97%)
In one study, oral nifedipine was used.(51) The authors report
a significant problem with patient compliance in this treatment arm secondary to side effects, slow fissure healing, and minimal symptomatic improvement Overall 41% of patients in the oral nifedipine group experienced these problems, and 70% withdrew from the study While these patients were analyzed on an inten-tion to treat basis, the effect of oral nifedipine on fissure healing may have been substantially decreased In contrast, Katsinelos and colleagues measured a high rate of fissure healing after treatment with nifedipine ointment (97%) that was not significantly
differ-ent from fissure healing after sphincterotomy (100%, p = 0.49).
(52) The increased treatment effect of nifedipine ointment may be secondary to a higher dose that was used in this study compared to others (0.5% vs 0.2%) In addition, topical calcium channel antag-onists have been proven more effective than oral preparations in fissure healing and side effect profile.(53) Overall, these studies suggest that oral calcium channel antagonists do not increase fis-sure healing rates but do increase side effects However, increases
in ointment concentrations may increase treatment efficacy with-out a change in adverse side effects
Table 20.3 Randomized Controlled Trials of Calcium Channel Blockers for the Treatment of Chronic Anal Fissure.
author/
year
number
of Patients
treatment groups (% ointment)
length of treatment (weeks)
Fissure healing (%)
overall Side effects (%)
Follow-up (months)
recurrence (%)
Perrotti
2002 (45)
110 1.5 lidocaine + 1.0
hydrocortisone vs 0.3 N BID
6 16 vs 95
(p < 0.001) None 18 (p = NR)55 vs 6
Kocher
2002 (47)
60 0.2 GTN vs 2 D BID 6–8 86 vs 77
(p = 0.21) (p = 0.01) 72 vs 42 3 (p = NR)2 vs 0 Bielecki
2003 (46)
43 0.5 GTN vs 2 D BID 8 86 vs 86
(p = 0.95) (p = NR)33 vs 0 None NR
Ezri
2003 (49)
52 0.2 GTN vs 0.2 N QID 24 58 vs 89
(p < 0.04) (p < 0.01)40 vs 5 12 (p = NR)31 vs 42
Mustafa
2005 (50)
20 0.2 GTN vs 20 mg PO N BID 8 70 vs 60
(p = NS) (p = NR)30 vs 10 3 (p = NR)0 vs 10
Shrivastava
2007 (48)
90 P vs 0.2 GTN vs 2 D BID 6 33 / 73 / 80
(p = <0.02) 0 / 67 / 0 (p = NR) 12 13 / 32 / 50 (p < 0.015)
Ho
2005 (51)
132 LIS vs TS vs 20 mg PO N BID 6 96/ 95/ 16
(p < 0.001) difference in No
continence
4 0/ 2.4/ 57
(p = 0.003)
Katsinelos
2006 (52)
64 LIS vs 0.5 N TID 8 100 vs 97
(p = 0.49) (p = NR)19 vs 50 20 (p = NR)0 vs 7 Jonas 2001
(53)
50 60 mg PO D vs 2 D BID 8 38 vs 65
(p = 0.09) (p = 0.001)33 vs 0 6 (p = NR)11 vs 7
Note: N = nifedipine; BID = two times per day; NR = not recorded; GTN = glyceryl trinitrate; D = diltiazem; QID = four times per day; NS = not statistically significant; LIS = lateral internal sphincterotomy; TS = tailored sphincterotomy; TID = three times per day.
Trang 8In summary, topical calcium channel antagonists may be used
in the treatment of chronic anal fissure They have similar efficacy
to nitrates with a lower occurrence of side effects Topical
prepa-rations of nifedipine or diltiazem are preferred over oral
prepara-tions due to a higher fissure healing rate and fewer side effects
compared with oral administration Sphincterotomy remains the
gold standard for healing of chronic anal fissure, but given the
chance for incontinence after surgery, topical calcium channel
antagonists are preferred for first line therapy
Botulinum toxin
Botulinum toxin (BT) is an exotoxin produced by the bacterium
Clostridium botulinum BT has been used medically in the treatment
of multiple diseases in which there is muscular hypertonicity Chronic
anal fissure is characterized by internal anal sphincter (IAS)
hyperto-nia and has been treated with BT since 1993 The exact mechanism
of BT on internal anal sphincter relaxation is still unclear In striated
muscle, BT binds to presynaptic nerve terminals and prevents the
release of acetylcholine, resulting in paralysis However, in smooth
muscle, BT reduces the release of excitatory neurotransmitters from
sympathetic nerves and probably causes IAS relaxation through
sympathetic blockade.(54) Manometric studies demonstrate a
sus-tained decrease in mean anal resting pressure (MARP) when BT is
injected into the internal anal sphincter This sustained reduction in
MARP is in contrast to the short-lived relaxation seen in response to
GTN therapy This longer period of IAS relaxation after BT injection
may lead to higher rates of chronic anal fissure healing secondary to
improved blood flow to the posterior commissure
Multiple studies have been performed to determine the
opti-mal dose and method of delivery for BT to the IAS Most studies
have been performed to determine the BT dose with the highest fissure healing rate and the least amount of complications.(55–59) All these studies show that fissure healing rates are improved with increasing BT doses Botox doses as high as 40–50 units of have been used in a single injection Increasing doses do not lead to higher complication rates but do lead to more significant decreases
in MARP from baseline.(57) This increased efficacy is secondary
to a dose dependent diffusion of the toxin through the IAS muscle Higher BT doses have a direct effect throughout the muscle whereas smaller BT doses demonstrate a gradient of paralysis through the muscle length.(58) Other factors which may lead to variations in clinical response are differences in drug dilution volumes, number
of injection sites, presence or absence of antibodies, variations in active drug, and susceptibility of target cells Maria et al examined the role of BT injection site on fissure healing.(60) Their hypothesis was that posterior injection of BT leads to impaired diffusion of the toxin secondary to increased fibrosis around posterior fissures Indeed, they found that 20 units of Botox on either side of the ante-rior midline resulted in lower mean anal resting pressures as well as higher fissure healing rates compared to 20 units of Botox admin-istered on either side of the posterior midline Results from these studies show BT is safely administered in high doses (30–40 units Botox) as initial therapy and may be more effective if administered
in the anterior rather than posterior midline
Botulinum Toxin versus Placebo
Three randomized studies have evaluated BT efficacy in com-parison to a “placebo” treatment.(61–63) (Table 20.4) In two studies, normal saline injections of a volume equal to that of the toxin used, were injected into the IAS.(62, 63) In the third
Table 20.4 Randomized Controlled Trials of Botulinum Toxin for the Treatment of Chronic Anal Fissure.
author/
year
number of
Patients treatment groups Fissure healing (%) Side effects (%)
Follow-up (months) recurrence (%)
Maria
1998 (57)
30 0.4 ml saline vs 20 U B 13 vs 73 (p = 0.003) IC flatus: 3.3 overall 4 None
Colak
2002 (61)
62 Lidocaine BID 4 wks vs 50 U B 21 vs 71 (p = 0.006) None 2 NR
Siproudis
2003 (62)
44 0.4 ml saline vs 100 U Dysport 32 vs 32 (p = NS) Perianal
thrombosis: 9.1 vs 18.2 Abscess: 13.6 vs 4.5
3 9.1 vs 13.6
(p = NS)
Brisinda
1999 (64)
50 0.2%GTN BID 6 wks vs 20 U B a 60 vs 96 (p = 0.005) GTN: 20% HA
BT: None
15 None
DeNardi
2006 (66)
30 0.2% GTN BID 8 wks vs 20 U B 3 months: 67 vs 47 (p = 0.51) GTN: 20% HA
BT:None
36 33 vs 33
(p = NS)
Fruehauf
2006 (67)
50 0.2% GTN BID 2 wks vs 30 U B 2 weeks: 52 vs 24 (p < 0.05) 26% overall
GTN: 48% HA
Brisinda
2007 (65)
100 0.2% GTN TID 8 wks vs 30
U B a
70 vs 92 (p = 0.009) GTN: 34% HA
BT: 6% IC flatus
21 20 vs 0
(p = NR)
Mentes
2003 (71)
101 LIS vs 0.3U/kg BT (20U or
30U) B
98 vs 74 (p < 0.001) IC: 8 vs 0 12 5 vs 11
(p = NR)
Iswariah
2005 (70)
38 LIS vs 20 U B 6 weeks: 86 vs 41 (p = 0.004) IC: no difference 6 10 vs 53
(p < 0.05)
Arroyo
2005 (69)
80 LIS vs 25 U B 12 months: 93 vs 45 (p < 0.001) IC: 7.5 vs 5 (p = NS) 36 7.5 vs 55
(p < 0.001)
Note: B = Botox; IC = incontinence; BID = two times per day; NR = not reported; NS = not statistically significant; GTN = Glyceryl trinitrate; HA = Headache; TID = three times per day; LIS = Lateral Internal sphincterotomy
a Crossover after 2 months treatment.
Trang 9improved outcomes in colon and rectal surgery
study, lidocaine ointment was applied twice daily and with bowel
movements for a 4 week period.(61) In two studies, there was a
significant difference in fissure healing between placebo and BT
treated patients (13–21% vs 71–73%).(61, 63) In the third, there
was no measured difference in fissure healing between the two
groups (32%).(62) Maria et al also reported a 25%
posttreat-ment decrease in MARP from baseline in the toxin group but not
in the placebo group.(63) Reported side effects in these studies
were minimal with incontinence to flatus in one patient,
peri-anal thrombosis in six and periperi-anal abscess in four of 136 total
patients The recurrence rate was not consistent among these
studies with reports of no recurrence compared to a high of 13%
in the BT treatment group after 4 months The different findings
in these three studies which compare BT to placebo for chronic
anal fissure may be explained by methodological differences and
baseline differences in the study groups at randomization In one
trial there were more men and higher maximal voluntary anal
squeeze pressures in the placebo group as compared to the BT
treated group.(63) This may have lead to a difference in
treat-ment effect Also, one trial was not able to be blinded
second-ary to the use of ointment in the placebo group and injection in
the toxin group.(61) It is unclear whether clinicians who were
grading fissure healing were blinded to randomized treatment
groups Finally, the third study was stopped early before
reach-ing the intended sample size because of newly published
stud-ies demonstrating BT efficacy in fissure healing Despite these
methodological differences and group differences after
rand-omization, these studies suggest that BT is superior to placebo in
the healing of chronic anal fissure
Botulinum Toxin versus Nitrates
Four randomized trials have compared the efficacy of BT to GTN
ointment.(64–67) (Table 20.4) In each trial there were differences
in the length of treatment (2–8 weeks) and application frequency
(2–3 times per day) of GTN ointment There were also differences
in the dose of BT used with two studies using 20 units of Botox
and the other two studies using 30 units Two studies found a
sig-nificant improvement in anal fissure healing for patients treated
with BT compared to 0.2% GTN ointment (92–96% vs 60–70%)
(64, 65) A third study measured an advantage of GTN treatment
administered over 2 weeks compared to BT (52% vs 24%).(67)
These findings are surprising given the previous studies which
show 4–8 weeks are needed to achieve fissure healing with GTN
treatment In the fourth study, there was no difference in
treat-ment efficacy between BT and GTN ointtreat-ment administered over
8 weeks.(66) However, this is the smallest of the four studies and
may not have been adequately powered to measure a difference
in treatment efficacy Patients treated with GTN ointment were
more likely to suffer adverse side effects (20–34% headache) in
comparison to BT treated patients (0–6% temporary
inconti-nence to flatus) Fissure recurrence was more frequent in GTN
treated patients in one study (65) but not in another.(66) In a
dif-ferent study, long-term fissure recurrence after BT treatment was
42% after 42 months.(68) Overall, these studies show a benefit of
BT compared to GTN in terms of short term fissure healing and
adverse medication effects Frequent fissure recurrence after GTN
and BT treatment has been observed
In two studies of GTN versus BT treatment crossover was per-formed at 2 months.(64, 65) Patients who did not heal with their initial treatment and accepted the alternative treatment were able to achieve fissure healing with the alternative treatment In both studies, patients who failed BT and then received GTN (8 patients), expe-rienced fissure healing within 2 months Twenty one patients who failed GTN and then received BT achieved fissure healing within 2 months These studies suggest that patients who fail initial therapy with GTN or BT, can be successfully treated with an alternative med-ical therapy before surgmed-ical treatment is considered
Botulinum Toxin versus Sphincterotomy
There are three randomized studies which compare outcomes for patients receiving either BT or internal sphincterotomy (IS) (69–71) (Table 20.4) In these studies, IS was superior to BT for fissure healing (86–98% vs 41–75%) While sphincterotomy is usually avoided secondary to fears of incontinence, there was no significant difference in continence scores in any of these four studies Incontinence after fissure treatment with either BT or sphincterotomy was associated with lower mean anal resting pressures after treatment and age >50 years.(69) Fissure recur-rence was also more common in BT treated patients compared to
IS treated patients.(69, 70) Recurrences were seen 6–12 months after fissure healing.(69) Recurrence was associated with certain clinical and manometric risk factors These include symptom duration greater than 12 months, presence of a sentinel pile, persistently elevated mean anal resting pressure and amount of time slow wave and ultra slow waves are present on manometric examination Based on these studies, patients who are at high risk
of anal fissure recurrence should undergo IS as a first line ther-apy In patients who are at high risk of incontinence after IS, the first line therapy should be BT since healing can be achieved with lower complications even if repeat injection is required
Overall, BT injections can be used for the treatment of chronic anal fissure with improved fissure healing rates compared to placebo and GTN Fissure healing may take longer after BT treat-ment when compared to fissure healing after IS, but is associated with few complications Patients at high risk of incontinence (age>
50 yrs, previous anorectal surgery, multiparous females, diagnosis
of inflammatory bowel disease) should be treated with BT before
IS Anal fissure recurrences after BT treatment are common, but can be treated with repeat BT injection without adverse effects
SurgiCal theraPy
While surgical treatment of chronic anal fissure has been employed since the 19th century, improved pathophysiologic understanding in the middle of the 20th century, led to the reintroduction of surgical treatments In 1964, Watts, Bennett and Goligher described stretch-ing of the anal sphincter with fstretch-inger dilation, and Eisenhammer recommended sectioning the internal anal sphincter to reduce sphincter resting pressure.(72, 73) Since their initial description, anal dilation and sphincterotomy have been used in numerous randomized controlled trials to determine the ideal surgical treat-ment for chronic anal fissure Overall there is a clear benefit of sphincterotomy compared to anal stretch for fissure healing and postoperative incontinence This has been confirmed in clinical tri-als as well as manometric evaluations After sphincterotomy, mean
Trang 10anal resting pressure is permanently reduced in patients with anal
fissure who have been shown to have significantly elevated
preop-erative resting pressures compared to controls.(74) Yet, the initial
surgical techniques of Watt and Eisenhammer have been revised
with multiple studies comparing the efficacy of modified surgical
interventions on fissure healing, recurrence, anal resting pressure,
and treatment complications such as incontinence
Anal Dilatation
Anal dilation has been used in three different forms for the
treat-ment of chronic anal fissure Gentle, graduated anal dilation
has been accomplished with standardized anal dilators (20–27
mm) which are increased in size over several weeks of treatment
Anal dilation has also been achieved with a one time pneumatic
balloon dilation of the sphincter to 1.4 atmospheres Finally, anal
dilation has been performed using anal stretch with 4–6 finger
dilation of the sphincter All these techniques have been criticized
for the poorly controlled sphincter stretch that results in damage
to both the internal and external sphincter The result of
uncon-trolled sphincter stretch can lead to high rates of incontinence
for both flatus and stool that may be permanent In reality, each
of these forms of anal dilation lead to variable degrees of control
over the amount of sphincter stretch and thereby affect fissure
healing, recurrence, and incontinence rates differently
The forceful anal stretch procedure has the least amount of
standardization on sphincter dilation It has been compared to
the gold standard, internal anal sphincterotomy, in five
rand-omized controlled trials.(75–79) Three of these studies found that
internal sphincterotomy was superior to anal stretch secondary to
higher fissure healing rates (90–97% vs 70–71%) with
signifi-cantly lower rates of incontinence (3.3–20% vs 20–39%).(75–77)
The other two studies found an advantage in fissure healing rates
after anal stretch at 4 month follow-up with comparable rates of
fissure recurrence and incontinence.(77, 79) However, these two
studies have been criticized for high drop out rates, short
follow-up, and question of inadequate sphincterotomy Overall, internal
sphincterotomy is superior to forceful anal stretch for the surgical
treatment of chronic anal fissure
Given previous criticisms, techniques for controlled anal stretch
have been developed When graduated anal dilators are used over
several weeks, the effect on fissure healing is inconsequential and
not better than placebo.(80) The addition of heat to anal dilators
along with nitroglycerin ointment may lead to improved fissure
healing rates (94% at 12 months) (81) However, this was a small
study which has not been replicated Controlled anal stretch
with increased dilation effect has been attempted with
pneu-matic balloon dilation In a prospective clinical trial, Renzi and
colleagues measured the effect of anal balloon dilatation to 1.4
atmospheres over six minutes In 33 patients, 94% healed within
5 weeks of treatment, 3% recurred over 12 months and 6% of
patients had transient incontinence These treatment effects were
achieved with a measureable decrease in anal resting pressure
with no visible sphincter defect on endorectal ultrasound.(82)
This study was followed by a randomized controlled trial of 36
patients who received either pneumatic sphincter dilatation or
nitroglycerin ointment.(83) At 30 days, 95% of patient
undergo-ing pneumatic sphincter dilation had healed fissures compared
to 40% of patients who received nitroglycerin ointment While local wound problems such hemorrhoid thrombosis occurred in the short-term, there were no patients who complained of prob-lems with continence after pneumatic dilation In all, graduated anal dilation is not more effective than placebo for the treatment
of chronic anal fissure, while pneumatic balloon dilation of the sphincter may result in improved fissure recurrence and incon-tinence rates than those seen with forceful anal dilation Further studies of pneumatic balloon dilation are needed to see if it is in fact comparable to internal sphincterotomy
Sphincterotomy
Internal sphincterotomy has also been subjected to revisions in technique Initially, Eisenhammer described division of the exter-nal sphincter and then modified his technique to that of the inter-nal sphincter at the posterior midline.(73) Overtime, it became apparent that fissurectomy with posterior midline sphinctero-tomy resulted in a “keyhole deformity” or deep furrow in the excision site which interfered with closure of the anal canal while
at rest.(84) This deformity lead to increased rates of incontinence compared to lateral sphincterotomy with longer healing times (78) Posterior sphincterotomy has subsequently been abandoned
in favor of lateral internal sphincterotomy
Lateral internal sphincterotomy has also been performed in an open and closed fashion The open technique involves a 1–2 cm skin incision over the intersphincteric groove and lateral to the anal canal.(85) The internal anal sphincter is then separated from the external sphincter and mucosa up to the dentate line so that
it can be divided under direct vision Closed internal sphincter-otomy was first described by Notaras in 1969.(86) With this tech-nique, an 11 blade scalpel is inserted through the anoderm into the intersphincteric plane While using a finger for guidance, the surgeon rotates the blade 90 degrees and an internal sphincterot-omy is performed upto the dentate line Given the blind technique
of closed internal sphincterotomy, surgeons have questioned the adequacy of sphincter division using this technique In fact, closed sphincterotomy has been compared to open sphincterotomy in
4 randomized controlled trials with 299 patients.(87–90) All four studies found equivalent rates of fissure healing (90–100%), and recurrence (0–10%) Incontinence occurred infrequently (4.1– 7.5%) and improved with time Therefore, both open and closed techniques have been shown through randomized controlled trials to have equal outcomes
Surgical treatment of chronic anal fissure can lead to variable rates of incontinence to gas and liquids that can be temporary or permanent In an effort to reduce rates of incontinence after sphinc-terotomy, investigators have sought to determine the optimal length
of sphincterotomy which allows for fissure healing but minimizes postoperative incontinence Two randomized studies have exam-ined the role of sphincterotomy length on fissure healing, recur-rence, and incontinence In these studies, limited sphincterotomy
to the fissure apex was compared to a full sphincterotomy to the dentate line.(91–92) Fissure healing rates were similar (88–100%)
in both studies In one study there was no fissure recurrence after
24 weeks of follow-up (91), and, in the other, there was a 13.2% treatment failure rate in the limited sphincterotomy group.(92) There were also short-term differences in incontinence between